Mutations in additional sex comb-like 1 (ASXL1) gene were recently demonstrated in various myeloid malignancies, but have not been comprehensively investigated in acute myeloid leukemia (AML). In this study, we analyzed ASXL1 mutations in exon 12 in 501 adults with de novo AML.
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Introduction
Recent advances in the research of acute myeloid leukemia (AML), especially the identification of novel genetic mutations, have enabled us to stratify this heterogeneous disease entity into distinct subtypes beyond the scopes of cyto-morphology and cytogenetics. The progress not only brings us insight into the pathogenesis of AML, but also helps refine the treatment strategies for this group of patients. 1 Recent studies have identified mutations of the Additional sex comb-like 1 (ASXL1) gene in various types of myeloid malignances, including myelodysplastic syndrome (MDS), myeloproliferative neoplasia (MPN), MDS/MPN, and primary and secondary AML. [2] [3] [4] [5] [6] ASXL1 is a human homologue of the Additional sex combs (Asx) gene of Drosophila, and is mapped to chromosome 20q11, a region commonly involved in cancers. 7 This gene is highly conserved among multiple species. It consists of an N-terminal ASX Homology (ASXH) domain and a C-terminal plant homeodomain (PHD) zinc finger region. [7] [8] In Drosophila, Asx is categorized as a member of the Enhancer of Trithorax and Polycomb (ETG) group because mutations of Asx enhance the homeotic transformation of both trithorax and polycomb gene mutations. [9] [10] In human, the exact functions of ASXL1 remain to be defined, but it can act as a ligand-dependent coactivator for retinoic acid receptor through binding with SRC-1 (steroid receptor coactivator-1), a nuclear receptor co-activator. 11 Moreover, ASXL1 is involved in regulation of histone methylation by cooperation with HP1 (heterochromatin protein-1) to modulate the activity of LSD1, 12 
a histone
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From demethylase for H3K4 and H3K9. 13 Given the tremendous impact of aberrant epigenetic modification in the pathogenesis of AML, [14] [15] we expect that ASXL1 mutation might play an important role in leukemogenesis.
Although ASXL1 mutation has been reported in de novo AML, the number of patients studied was relatively small (less than 50 at most), and the characteristics of AML bearing this mutation and its prognostic impact have not been comprehensively studied till now. We thus examined this mutation in 501 de novo AML patients and found that ASXL1 mutation occurred with similar frequency in patients with a normal karyotype (NK) and those with abnormal cytogenetics (8.9%
vs.12.9%, p=0.179), and was associated with distinct clinical and biological characteristics that have not been reported yet. Moreover, sequential studies of ASXL1 mutations in 269 samples from 127 patients during the clinical follow-ups showed that two out of the six relapsed ASXL1-mutated patients studied lost the original mutation at relapse and/or refractory status, while two ASXL1-wild patients (2/109) acquired novel mutations during disease progression, suggesting instability of this gene mutation during disease evolution.
Materials and Methods

Patients
Six hundred and seventy four adults with de novo AML were newly diagnosed in the National Taiwan University Hospital from 1995 to 2007. The diagnosis of AML was based on
French-American-British (FAB) classification system. Among them, 501 patients (74.3%) had , including FLT3-ITD, FLT3-TKD, MLL-PTD, CEBPA,   NPM1, PTPN11, NRAS, KRAS, JAK2 , KIT, AML1 (RUNX1), WT1, and IDH1 was performed as described previously. [17] [18] [19] [20] [21] [22] [23] The ASXL1 exon 12 till the stop codon was amplified by 3 pairs of primers and sequenced by another 6 internal primers, as described by Gelsi-Boyer et al, 2 lymphoid-associated antigens (CD2, CD5, CD7, CD19, CD10 and CD20) , and the lineage non-specific antigens (HLA-DR, CD34 and CD56). The antibodies for CD15, CD16, CD2, and HLA-DR were purchased from BD Biosciences (San Jose, California, USA). The other antibodies were purchased from Immunotech (Marseille, France). The method was described previously.
Mutation analysis
Determination of mutations in various genes
21
Cytogenetic analysis
Bone marrow cells were harvested directly or after 1-3 days of un-stimulated culture and the metaphase chromosomes were banded by the G-banding method as described earlier.
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Gene cloning
When ASXL1 mutations at diagnosis were no longer seen in relapsed samples by direct sequencing, we cloned the PCR products spanning the original mutation spots by TA cloning (Yeastern Biotech, Taipei, Taiwan) as described previously, 25 followed by sequencing of at least 30 individual clones to search for any mutation.
Statistics
Mann-Whitney tests were used to calculate the significance if the continuous data were not normally distributed while comparing the adult AML patients with or without ASXL1 mutation. Disease free survival (DFS) was measured from the date when the patients achieved CR to the date of relapse or last follow-up. Multivariate Cox proportional hazard regression analysis was used to investigate independent prognostic factors for OS and DFS. Kaplan-Meier estimation was used to plot survival curves, and log-rank tests were used to calculate the difference of OS and DFS between groups. A p value less than .05 was considered statistically significant. All statistical analyses were performed with SPSS 17 software (SPSS Inc).
Results
ASXL1 mutations
A total of 501patients with de novo AML were included in this study. There were 216 females and 285 males, with a median age of 52 years (range, . The basic demographic data are listed in Supplementary Table 2 . ASXL1 mutations, including frame-shift and non-sense mutations, at exon 12 occurred in 54 patients (10.8%) at diagnosis. All these mutations resulted in disruption of the PHD domain of ASXL1 ( Moreover, the amino acids at these sites are not well conserved among human, mouse, zebra fish, and fugu fish (data not shown). The basic clinical and biological data of the patients with ASXL1 mutations are listed in Table 1 .
Correlation of ASXL1 mutations with clinical features and biological characteristics
There was no significant difference in white cell count, hemoglobin, platelet count, and serum lactate dehydrogenase (LDH) levels between patients with and without ASXL1 mutation (data not shown). However, ASXL1 mutations occurred more frequently in older (median age 66 vs. 49 years, p<0.001) and male patients (13.7% vs. 6.9%, p=0.012) and were closely associated with FAB M0 subtype (p=0.016), isolated trisomy 8 (p=0.011) ( Table 2 ) and expression of HLA-DR (p<0.001) and CD34 (p=0.020) (Supplementary Table 3 ). There was a trend of positive correlation between ASXL1 mutation and t(8;21) (p=0.067). The incidence of ASXL1 mutations in patients of 60 years or older was 18.0% (34/189), compared with 5.4% (20/312) in patients younger than 60 years. In contrast, ASXL1 mutations were inversely related to FAB M1 subtype (p=0.003), t(15;17) (p=0.025), complex cytogenetics (p=0.047) ( Table 2) , and expression of CD33 (p=0.036) and CD15 (p=0.024) (Supplementary Table 3 ). None of the 38 patients with APL and the 19 patients with inv(16) had ASXL1 mutation at diagnosis (Table 2 ). ASXL1 mutations occurred with similar frequency in patients with a NK and those with abnormal cytogenetics (8.9% vs.12.9%, p=0.179, Table 2 ).
Association of ASXL1 mutations with other gene mutations
We also examined the association of ASXL1 mutations with 13 other gene mutations (Table 1 and For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Table 3 ). Thirty nine of the 54 patients with ASXL1 mutation had concurrent other gene mutations at diagnosis; 31patients had one, seven had two, and one had three additional mutations ( Table 1 ).
The patients with ASXL1 mutations had significantly lower incidences of NPM1 mutation, WT1 mutation, and FLT3-ITD (3.7% vs. 23.0%, 0 vs. 7.4%, and 7.4% vs. 25.0%, respectively, Table 3 ).
On the contrary, ASXL1 mutation cooperated frequently with RUNX1 mutation (16/54, 29.6% vs 45/447, 10.1%, p<0.001).
Influence of ASXL1 mutation on treatment response and survival
Survival analyses were performed in 360 AML patients who received standard intensive chemotherapy after diagnosis, as described previously.
26-27
Sixty-nine patients were older than 60 years; 17 of them had ASXL1 mutation. The 360 patients included in survival analyses were younger than total cohort (Supplementary Table 2 ) and had a higher incidence of t(15;17) ,but lower incidence of complex chromosome abnormalities. There were no differences in other characteristics between these two groups. The median follow-up time of our patients was 53 months (ranges, 1.0 to 160). Patients with ASXL1 mutations had a lower CR rate than others (15/26, 57.7%, vs. 267/334, 79.9%, p=0.013), but the relapse rate was similar between the two groups once they obtained a CR (data not shown). Patients with ASXL1 mutation had worse OS (median OS: 14 months vs. 58 months; p=0.009) ( Fig. 2A and Table 4 ). When the outcome was analyzed separately for the younger and older patients, the OS was not different between the patients with and without ASXL1 mutation in the younger group of patients with age of 60 years or less (n=291, median 22±9.3 mo vs. not reached, p=0.221), nor in the group older than 60 years (n=69, median 8±7.5 mo vs. 11±2.5 mo, p=0.093). The lack of difference of survival after this age division may be related to the smaller number of patients in each group, compared to the total cohort. In multivariate analysis using covariables that were significantly associated with OS in univariate analysis such as age, karyotypes, NPM1mutation without FLT3-ITD
, RUNX1 mutation, WT1 mutation, and biallelic CEBPA mutations (Table 4) , we could not establish ASXL1 mutation as an independent poor prognostic factor for OS, even only non-APL patients or those with intermediate cytogenetics were analyzed ( Table 5) .
Analysis of ASXL1 mutation in sequential samples
We also determined the stability of ASXL1 mutations during clinical follow-ups in 269 samples from 127 patients, 18 with ASXL1 mutations and 109 without (Table 6 ). Among the 18 ASXL1-mutated patients, the ASXL1 mutations disappeared in 15 patients ( Supplementary Fig. 1A ), but were retained in UPNs 7, 12, and 33 in clinical CR (Table 6 ). The mutant signals in CR samples from all these three patients were less intense ( Supplementary Fig. 1B ), compared with those at diagnosis or relapse, suggesting there were still leukemia cells but in lower amount in the samples, despite of the morphological remission. In consistency with the findings, the NRAS mutation and RUNX1 mutation were also detectable in the CR samples of UPNs 7 and 33, respectively (Table 6 ). For UPN 12, his ASXL1 mutation was G646WfsX12, which was the most common mutation in this study and was suggested to be acquired since it disappeared in CR in Fig. 1C and D) . In UPN 30, the mutation could be demonstrated in one out of 20 clones by TA cloning, but was obviously lost as the disease became refractory. The c-KIT mutation site in this patient also changed from exon 8 at diagnosis to exon 17 at disease relapse and refractoriness. In UPN 53, the original ASXL1 mutation could not be detected at relapse by both direct sequencing and TA cloning, and was replaced by a new non-sense mutation ( Supplementary   Fig. 1D ). FLT3-TKD mutation in this patient also disappeared at the same time (Table 6 ). For 109 patients without ASXL1 mutation at diagnosis, two (UPNs 55 and 56) acquired a novel ASXL1 mutation (c.1934dupG) at relapse (Supplementary Fig. 1E and Table 6 ). Sequencing for 36 and 30
clones, respectively, using the DNA from diagnostic samples of these 2 patients did not yield any
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From mutant clone, suggesting that either the ASXL1 mutation was newly formed at relapse or was present in low level below 3% at the time of diagnosis. These results indicate that ASXL1 mutation status can change during disease evolution.
Discussion
Although ASXL1 mutations have been reported in various myeloid malignancies, several important questions remain unsolved. [2] [3] [4] [5] [6] First, the incidence of this mutation in de novo AML is still not clearly defined, ranging from 6.5% (3/46) to 29.6% (8/27) in two studies with relatively small number of patients. [5] [6] Secondly, the association of this mutation with karyotypes has also not been well addressed yet. For example, 40% (34/86) of MDS/AML patients with NK were found to have ASXL1 mutation in one study, 6 but only 13.0% (6/46) of such patients had this mutation in another study. 5 Thirdly, ASXL1 mutation was shown to be mutually exclusive with NPM1 mutation 5 , but the association of this mutation with other genetic mutations as well as other biological features in ASXL-mutated AML remains unknown. Finally, no studies have investigated the impact of this mutation on clinical outcome.
In this study, we tried to solve these issues by focusing on a large cohort of de novo AML patients. We found that around 10% of primary AML patients had ASXL1 mutations. Unlike other common genetic mutations in AML such as FLT3-ITD, and mutations of NPM1, CEBPA, and IDH1, which are significantly more common in patients with a NK, 17-18, ASXL1 mutation frequently cooperated with RUNX1 mutation in the same patients, but was mutually exclusive with NPM1 mutation (p<0.001), similar to the previous report. 5 It was also inversely associated with WT1 mutation (p=0.038) and FLT3-ITD (p=0.003), which have not been reported before. The close association of ASXL1 mutation with RUNX1 mutation and a trend to be positively correlated with t(8;21), a translocation resulting in RUNX1-ETO fusion, suggest this mutation may closely cooperate with mutations of RUNX1, which has been implicated in chromatin modification of hematopoietic system, in leukemogenesis.
30-31
We found that ASXL1 mutation was associated with a worse OS (median 14 vs. 58 months, (Table 4 and 5). This may be related to the fact that ASXL1 mutation was highly associated with old age and RUNX1 mutation, two poor prognostic factors, 26,32 but other possible reasons await for exploration. Although ASXL1 mutations in our analysis did not represent a significant independent factor for prognosis, it is highly associated with a worse survival and lower CR rate. Thus, we can predict a worse prognosis for the patients bearing this mutation.
At present, determination of ASXL1 mutations in routine clinical practice may not be necessary, but as more and more knowledge about this mutation comes out, the situation may change.
Out of the 109 ASXL1-wild patients, two acquired a G646WfsX14 mutation of ASXL1 at disease relapse (Table 6 and Supplementary Fig. 1E ). This finding implies that ASXL1 mutation can be acquired as diseases evolve into a late stage, similar to the situation in MDS 6 . In addition, in one out of the six ASXL1-mutated patients who had relapse and were studied, the ASXL1 mutation detected at diagnosis diminished at relapse and disappeared at refractory status (UPN 30 in Supplementary Fig. 1C and Table 6 ), and in the other one (UPN 53), the mutation was even replaced by a novel non-sense mutation as the disease further evolved ( Supplementary Fig. 1D , Table 6 ). Thus, this mutation may not be as good as NPM1 and IDH1 mutations 16, 25 to serve as a marker for monitoring of minimal residual disease.
The functions of ASXL1 in humans have not been well delineated, but several pieces of evidence indicate a role of this gene in chromatin modification. First, Asx in Drosophila, the homolog of human ASXL1, is a member of ETG genes, both of which are associated with histone modification. [9] [10] Secondly, the PHD domain at the C terminal of ASXL1 is well conserved among different species and can recognize methylated H3K4. 3, 7, [40] [41] [42] Finally, ASXL1 was shown to
LSD1, a H3K4 and H3K9 demethylase, in vitro. [12] [13] Given the important role of histone methylation in leukemogenesis, we expect that ASXL1 mutation may play an important role in the pathogenesis of AML.
In a recent report, ASXL1 c.1934dupG was suspected not a somatic mutation, but rather an artifact. 43 In that report, DNA from normal tissue (buccal mucosa) from ASXL1-mutated patients revealed c.1934dupG. Moreover, the same alteration was seen in more than 25% of samples from patients without obvious blood diseases. Since c.1934dupG is the most common ASXL1 mutation, this issue is critical in assessing the clinical and biological significance of ASXL1 mutations in myeloid neoplasms. Our data, however, strongly suggest that ASXL1 c.1934dupG is a somatic alteration, based on the following reasons: (1). The TA cloning of the PCR products from the samples with this mutation did yield mutant clones. In addition, repeated sequencing from both directions showed c.1934dupG (data not shown). The results from these 2 steps of studies indicate that c.1934dupG is not an artifact from sequencing per se. (2) . As mentioned in the results of sequential studies, in the 109 patients without ASXL1 mutation at diagnosis, only two acquired c.1934dupG at the time of relapse. That is, in the remaining 107 patients who did not have ASXL1 mutation at diagnosis, including 22 with more than one relapse, no c.1934dupG was detected in a total of 133 samples taken at the time of relapse, a finding in stark contrast to the report that c.1934dupG could be detected in up to 25% of control individuals without a hematologic malignancy 43 and arguing against the possibility that this mutation was an artifact randomly
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From occurring due to PCR errors. Moreover, all the mutations reported in our study were confirmed at least twice. Therefore, we are quite confident in the mutation results in our study. (3). Patients UPN16, 17, 21, 23, 24, 30, 40, and 44 had mutation c.1934dupG at diagnosis, but no more mutation was detected at the time of CR (Table 6 ). In UPN 16, subsequent relapse was accompanied with re-appearance of c.1934dupG. These results indicate that this mutation is not a random instance (please see Supplementary Fig. 1A for the sequencing patterns). We have also investigated ASXL1 mutations in additional 38 samples taken at the time of CR from the patients without this mutation at diagnosis, and none of them had detectable mutations (data not shown). This result suggests that c.1934dupG is very unlikely an artifact with a frequency as high as 25% in normal controls. The ASXL1 mutation in this relapsed sample could not be detected by sequencing of PCR products, but was detected in one of the 20 clones by TA cloning followed by sequencing of the individual clones. The mutation was not detectable by both direct sequencing and TA cloning in refractory status. # Mutation of c-KIT in these 2 samples was in exon 17, but the original c-KIT mutation in this patient was in exon 8.
@
This sample did not have original ASXL1 mutation, but gained a new non-sense mutation of ASXL1.
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